Results 151 to 160 of about 414,143 (313)

Editorial: Challenges of pharmacoeconomics in global health arena—Contemporary momentum in the early 2020s

Frontiers in Public Health, 2023
Mihajlo Jakovljevic, Mihajlo Jakovljevic, Mihajlo Jakovljevic, Nick Verhaeghe, Nick Verhaeghe, Kyriakos Souliotis, Kristijan Krstic   +6 more
doaj   +1 more source

Patients' preferences in periodontal disease treatment elicited alongside an IQWiG benefit assessment: a feasibility study

Patient Preference and Adherence, 2018
Vera Vennedey,1 Sonja HM Derman,2 Mickaël Hiligsmann,3 Daniele Civello,1 Anja Schwalm,4 Astrid Seidl,4 Fülöp Scheibler,5 Stephanie Stock,1 Michael J Noack,2 Marion Danner1,5 1Institute for Health Economics and Clinical Epidemiology ...
Vennedey V, Derman SHM, Hiligsmann M, Civello D, Schwalm A, Seidl A, Scheibler F, Stock S, Noack MJ, Danner M   +9 more
doaj  

Maine's lifelong learning accounts: good news for workers, businesses, and the economy [PDF]

Lifelong Learning Accounts (LiLAs) support current and future workforce needs. LiLA funds differ from tuition reimbursement in several ways: being available before course registration, being portable, and merging employee savings with contributions from ...
Auta Main
core  

The Use of Internal Rating Models in Managing the Risks Related to the Exposures of Non-banking Financial Institutions [PDF]

Although there is no express requirement in the regulations of the National Bank of Romania, the design, the implementation and the use of rating systems in the management of risks related to exposures of non-banking financial institutions (NFIs) on the ...
Bogdan Moinescu, Nicolae Dardac, Petronel Chiriac   +2 more
core  

How the HTAR will contribute to a value‐based decision‐making for medicinal products across the EU

British Journal of Clinical Pharmacology, EarlyView.
The European Union Health Technology Regulation 2021/2282 (HTAR) introduces joint assessment of health technologies (including medicinal products and medical devices) across EU Member States. It was signed into law in 2021 and came into full force in January 2025.
Roisin Adams, Michal Stanak
wiley   +1 more source

Beyond the label: Rethinking off‐label drug use in paediatrics. Towards a scientifically grounded and safer future for paediatric pharmacotherapy

British Journal of Clinical Pharmacology, EarlyView.
Abstract Despite regulatory progress being made in the past two decades, off‐label drug use in paediatrics remains pervasive, with prevalence estimated between 3% and 97% of prescriptions across different clinical settings. Off‐label use—defined as prescribing outside the conditions described in the Summary of Product Characteristics (SmPC)—is often ...
Tjitske M. van der Zanden, Miriam G. Mooij, Matthijs de Hoog, Saskia N. de Wildt   +3 more
wiley   +1 more source

Pharmaceutical distribution remuneration in Europe

Journal of Pharmaceutical Policy and Practice, 2015
Sabine Vogler, Lena Lepuschütz, Peter Schneider   +2 more
doaj   +1 more source

Do conditional marketing authorisations actually accelerate patient access? Time-to-access of conditional vs. standard marketing authorisations in Italy, Spain, and Germany. [PDF]

J Pharm Policy Pract
Ardito V, Falk L, Gasol Boncompte M, Pontes C, Robinson J, Schreyögg J, Ciani O.   +6 more
europepmc   +1 more source

Efficacy, safety and cost‐effectiveness of CAR‐T therapy

British Journal of Clinical Pharmacology, EarlyView.
CAR T‐cells demonstrate high efficacy in blood cancers, including ALL, MM and DLBCL. Innovations target solid tumours despite challenges such as antigen escape. Combination therapies enhance the delivery and infiltration of CAR T cells. Toxicity, cost and resistance remain major barriers to clinical use.
Emina Karahmet Sher, Amina Džidić‐Krivić, Emma Pinjic, Nejra Selak, Kanita Omerbasic, Alexandar Chupin, Andrej Belancic, Almir Fajkic   +7 more
wiley   +1 more source

Time-Driven, Activity-Based Cost Analysis of Secondary Intraocular Lens Implantation. [PDF]

J Vitreoretin Dis
Meshkin RS, Hoffman SE, Chaaya Md C, Pandiri S, Yannuzzi NA, Al-Khersan H, Ghorayeb G, Leung EH, Busquets MA, Gong DA, Kolomeyer AM, Niles PI, Lai MM, Grewal DS, Patel NA, American Society of Retina Specialists Health Economic Committee.   +15 more
europepmc   +1 more source